Charing Cross International News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Charing cross international. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Charing Cross International Today - Breaking & Trending Today

Hancock Jaffe Principal Investigator Dr. Jorge Hernando Ulloa Presents VenoValve One Year First-In-Human Data at Charing Cross International Symposium

Hancock Jaffe Principal Investigator Dr. Jorge Hernando Ulloa Presents VenoValve One Year First-In-Human Data at Charing Cross International Symposium
phoenixherald.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from phoenixherald.com Daily Mail and Mail on Sunday newspapers.

March Glickman , Jorge Hernando Ulloa , Michelle Mcadam , Hancock Jaffe , Exchange Commission , Charing Cross International Symposium , Hancock Jaffe Laboratories Inc , Drug Administration , Chronic Communications Inc , Hancock Jaffe Laboratories , Principal Investigator , Charing Cross International , Senior Vice President , Chief Medical Officer , Chronic Venous , Venous Insufficiency , Investigational Device Exemption , Jaffe Laboratories , Chronic Venous Insufficiency , Private Securities Litigation Reform Act , Chronic Communications , அணிவகுப்பு கிலிக்க்மன் , ஜார்ஜ் ஹெர்னாண்டோ யூலோவ , மைக்கேல் மக்யாடம் , ஹான்காக் ஜாஃப் , பரிமாற்றம் தரகு ,

Hancock Jaffe Principal Investigator Dr. Jorge Hernando Ulloa Presents VenoValve One Year First-In-Human Data at Charing Cross International Symposium

Provided by
Accesswire
Apr 23, 2021 4:40 PM UTC
IRVINE, CA / ACCESSWIRE / April 23, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that Dr. Jorge Hernando Ulloa, the Principal Investigator for HJLI s first-in-human VenoValve® study in Bogota, Colombia, presented one year data this past week at the Charing Cross International Symposium. The Charing Cross International Symposium is the longest-running vascular and endovascular global symposium in Europe and is attended by the world s leading experts in vascular and endovascular medicine.
Patients in the first-in-human study demonstrated significant improvement in all study endpoints including an aggregate 54% improvement in reflux (the backwards flow of blood), a 56% improvement in disease manifestations, as measured by venous clinical severity scores ( rVCSS ), and a 76% improvement in pain, as measur ....

March Glickman , Jorge Hernando Ulloa , Michelle Mcadam , Hancock Jaffe , Exchange Commission , Charing Cross International Symposium , Hancock Jaffe Laboratories Inc , Drug Administration , Chronic Communications Inc , Hancock Jaffe Laboratories , Principal Investigator , Charing Cross International , Senior Vice President , Chief Medical Officer , Chronic Venous , Venous Insufficiency , Investigational Device Exemption , Surgical Anti Reflux Venous Valve Endoprosthesis , Jaffe Laboratories , Chronic Venous Insufficiency , Private Securities Litigation Reform Act , Chronic Communications , அணிவகுப்பு கிலிக்க்மன் , ஜார்ஜ் ஹெர்னாண்டோ யூலோவ , மைக்கேல் மக்யாடம் , ஹான்காக் ஜாஃப் ,

Hancock Jaffe Laboratories, Inc.: Hancock Jaffe Principal Investigator Dr. Jorge Hernando Ulloa Presents VenoValve One Year First-In-Human Data at Charing Cross International Symposium

Hancock Jaffe Laboratories, Inc.: Hancock Jaffe Principal Investigator Dr. Jorge Hernando Ulloa Presents VenoValve One Year First-In-Human Data at Charing Cross International Symposium
April 23, 2021 /
Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that Dr. Jorge Hernando Ulloa, the Principal Investigator for HJLI s first-in-human VenoValve® study in Bogota, Colombia, presented one year data this past week at the Charing Cross International Symposium. The Charing Cross International Symposium is the longest-running vascular and endovascular global symposium in Europe and is attended by the world s leading experts in vascular and endovascular medicine. ....

March Glickman , Jorge Hernando Ulloa , Michelle Mcadam , Hancock Jaffe , Exchange Commission , Charing Cross International Symposium , Hancock Jaffe Laboratories Inc , Drug Administration , Chronic Communications Inc , Hancock Jaffe Laboratories , Principal Investigator , Charing Cross International , Senior Vice President , Chief Medical Officer , Chronic Venous , Venous Insufficiency , Investigational Device Exemption , Jaffe Laboratories , Chronic Venous Insufficiency , Private Securities Litigation Reform Act , Chronic Communications , அணிவகுப்பு கிலிக்க்மன் , ஜார்ஜ் ஹெர்னாண்டோ யூலோவ , மைக்கேல் மக்யாடம் , ஹான்காக் ஜாஃப் , பரிமாற்றம் தரகு ,